These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35536740)

  • 1. Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK.
    Wu R; Rison SCG; Raisi-Estabragh Z; Dostal I; Carvalho C; Robson J; Mihaylova B
    BMJ Open; 2021 Dec; 11(12):e052884. PubMed ID: 35536740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study.
    Mihaylova B; Wu R; Zhou J; Williams C; Schlackow I; Emberson J; Reith C; Keech A; Robson J; Parnell R; Armitage J; Gray A; Simes J; Baigent C
    Heart; 2024 Oct; 110(21):1277-1285. PubMed ID: 39256053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
    Wu R; Williams C; Zhou J; Schlackow I; Emberson J; Reith C; Keech A; Robson J; Armitage J; Gray A; Simes J; Baigent C; Mihaylova B;
    Br J Gen Pract; 2024 Mar; 74(740):e189-e198. PubMed ID: 38373851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
    Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
    Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
    Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
    Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
    Grover S; Coupal L; Lowensteyn I
    Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England.
    Ueda P; Lung TW; Lu Y; Salomon JA; Rahimi K; Clarke P; Danaei G
    PLoS One; 2018; 13(3):e0190688. PubMed ID: 29561843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term health outcomes of people with reduced kidney function in the UK: A modelling study using population health data.
    Schlackow I; Simons C; Oke J; Feakins B; O'Callaghan CA; Hobbs FDR; Lasserson D; Stevens RJ; Perera R; Mihaylova B
    PLoS Med; 2020 Dec; 17(12):e1003478. PubMed ID: 33326459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives.
    Jaspers NEM; Visseren FLJ; Numans ME; Smulders YM; van Loenen Martinet FA; van der Graaf Y; Dorresteijn JAN
    BMJ Open; 2018 May; 8(5):e021309. PubMed ID: 29804065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined antihypertensive and statin therapy for the prevention of cardiovascular events in patients with hypertension without complications: protocol for a systematic review and meta-analysis.
    Wang Y; Kuang ZM; Feng SJ; Jiang L; Chen QX; Ji XY; Cheng WL; Hu HJ
    BMJ Open; 2018 May; 8(5):e019719. PubMed ID: 29858408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted case finding in the prevention of cardiovascular disease: a stepped wedge cluster randomised controlled trial.
    Hemming K; Ryan R; Gill P; Westerby P; Jolly K; Marshall T
    Br J Gen Pract; 2016 Oct; 66(651):e758-67. PubMed ID: 27528707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
    Heller DJ; Coxson PG; Penko J; Pletcher MJ; Goldman L; Odden MC; Kazi DS; Bibbins-Domingo K
    Circulation; 2017 Sep; 136(12):1087-1098. PubMed ID: 28687710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
    Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
    PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach.
    Jackson R
    J Hum Hypertens; 1998 Sep; 12(9):607-13. PubMed ID: 9783489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.